RESUMEN
OBJECTIVES: To assess compliance with international guidelines for costly antifungal prescriptions and to compare these results with a first study performed in 2007. METHODS: Retrospective study including all costly antifungal prescriptions made in surgical and medical intensive care units and in a hepatobiliary, pancreatic, and digestive surgery unit. Prescriptions were assessed in terms of indication, dosage, and antifungal de-escalation. RESULTS: Seventy-four treatments were analyzed. Treatments were prescribed for prophylactic (1%), empirical (22%), pre-emptive (16%), or targeted therapy (61%). Caspofungin accounted for 68% of prescriptions, followed by voriconazole (20%) and liposomal amphotericin B (12%). Indication was appropriate in 91%, debatable in 1%, and inappropriate in 8%. Dosage was appropriate in 69%, debatable in 8%, and inappropriate in 23%. Prescriptions were inappropriate for the following reasons: lack of dosage adjustment in light of the hepatic function (10 cases), underdosage or excessive dosage by>25% of the recommended dose in seven cases. De-escalation to fluconazole was implemented in 40% of patients presenting with a fluconazole-susceptible candidiasis. CONCLUSION: The overall incidence of appropriate use was higher in 2012 compared with 2007 (62% and 37% respectively, P=0.004). Nevertheless, costly antifungal prescriptions need to be optimized in particular for empirical therapy, dosage adjustment, and potential de-escalation to fluconazole.
Asunto(s)
Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Anfotericina B/administración & dosificación , Anfotericina B/economía , Anfotericina B/uso terapéutico , Antifúngicos/administración & dosificación , Antifúngicos/economía , Caspofungina , Equinocandinas/administración & dosificación , Equinocandinas/economía , Equinocandinas/uso terapéutico , Femenino , Neoplasias Hematológicas/complicaciones , Trasplante de Células Madre Hematopoyéticas , Humanos , Lipopéptidos/administración & dosificación , Lipopéptidos/economía , Lipopéptidos/uso terapéutico , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica , Micosis/complicaciones , Micosis/mortalidad , Micosis/prevención & control , Trasplante de Órganos , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento , Voriconazol/administración & dosificación , Voriconazol/economía , Voriconazol/uso terapéutico , Adulto JovenRESUMEN
WHAT IS KNOWN AND OBJECTIVE: Ibrutinib is a recently approved oral anticancer agent with pharmacokinetics that is very sensitive to metabolic inhibition. We report a serious side effect of ibrutinib potentially attributable to interaction with the moderate CYP3A4 inhibitor verapamil. CASE DESCRIPTION: A patient with mantle cell lymphoma was admitted to our emergency department with severe diarrhoea. During a prescription review, the clinical pharmacist identified a potential drug interaction between ibrutinib and verapamil present in a branded combination product also containing trandolapril. Ibrutinib was discontinued for 5 days, and verapamil was stopped. Lercanidipine 10 mg daily was prescribed as an alternative antihypertensive drug. The patient was discharged after 3 days with symptomatic treatment for his diarrhoea. Three months later, the patient maintained control with ibrutinib and olmesartan, but without verapamil. WHAT IS NEW AND CONCLUSION: This is the first description of a serious side effect of ibrutinib likely due to an interaction with the CYP3A4 inhibitor verapamil. Prescriptions of ibrutinib must be carefully checked to identify possible interactions with CYP3A4 inhibitors and patients monitored accordingly.
Asunto(s)
Antineoplásicos/efectos adversos , Inhibidores del Citocromo P-450 CYP3A/efectos adversos , Pirazoles/efectos adversos , Pirimidinas/efectos adversos , Verapamilo/efectos adversos , Adenina/análogos & derivados , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Antihipertensivos/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Inhibidores del Citocromo P-450 CYP3A/administración & dosificación , Inhibidores del Citocromo P-450 CYP3A/farmacología , Diarrea/inducido químicamente , Dihidropiridinas/administración & dosificación , Interacciones Farmacológicas , Humanos , Linfoma de Células del Manto/tratamiento farmacológico , Masculino , Piperidinas , Pirazoles/administración & dosificación , Pirazoles/farmacocinética , Pirimidinas/administración & dosificación , Pirimidinas/farmacocinética , Verapamilo/administración & dosificación , Verapamilo/farmacologíaRESUMEN
INTRODUCTION: Our current development strategy integrates clinical pharmacy activities prioritized in surgical services. Patients in these services are typically risk patients: transfers, multiple prescribers, frequent medication change, pharmacotherapeutic risk classes. PATIENTS AND METHODS: Three clinical pharmacy activities (admission reconciliation, pharmaceutical analysis, participation doctors round) have been developed in orthopaedic surgery and neurosurgery. Pharmacists prospectively recorded data describing their activities: number of reconciliations and analyzed requirements and time required to achieve them. Data on pharmaceutical interventions were recorded on the basis ActIP®. The clinical significance of interventions was retrospectively rated by a team of two pharmacists and two physicians on the scale adapted Hatoum et al. RESULTS: Four thousand five hundred pharmaceutical analysis and 248 reconciliations were conducted. One hundred and fifty-six pharmaceutical interventions were issued. The average acceptance rate was 80%. A total of 5.8% of pharmaceutical interventions have been listed with a very significant clinical importance and 48.1% with at least significant clinical importance. The activities and documentation required pharmaceutical average daily time (senior pharmacist, resident and external pharmacist) about 6 hours. DISCUSSION AND CONCLUSION: Other studies, including comparative and medico-economic, must be conducted to support these results. Nevertheless, the indicators obtained attend a better readability of the clinical importance of the activities performed by clinical pharmacists and this particularly in surgical services, both by prescribers and authorities.
Asunto(s)
Cirugía General , Farmacéuticos , Servicio de Farmacia en Hospital/organización & administración , Humanos , Conciliación de Medicamentos , Preparaciones Farmacéuticas/análisis , Estudios ProspectivosRESUMEN
The medication iatrogenic events are responsible for nearly one iatrogenic event in five. The main purpose of this prospective multicenter study is to determine the effect of pharmaceutical consultations on the occurrence of medication adverse events during hospitalization (MAE). The other objectives are to study the impact of age, of the number of medications and pharmaceutical consultations on the risk of MAE. The pharmaceutical consultation is associated to a complete reassessment done by both a physician and a pharmacist for the home medication, the hospital treatment (3days after admission), the treatment during chemotherapy, and/or, the treatment when the patient goes back home. All MAE are subject to an advice for the patient, additional clinical-biological monitoring and/or prescription changes. Among the 318 patients, 217 (68%) had 1 or more clinically important MAE (89% drug-drug interaction, 8% dosing error, 2% indication error, 1% risk behavior). The patients have had 1121 pharmaceutical consultations (3.2±1.4/patient). Thus, the pharmaceutical consultations divided by 2.34 the risk of MAE (unadjusted incidence ratio, P≤0.05). Each consultation decreased by 24% the risk of MAE. Moreover, adding one medication increases from 14 to 30% as a risk of MAE on the population. Pharmaceutical consultations during the hospital stay could reduce significantly the number of medication adverse effects.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Administración del Tratamiento Farmacológico , Farmacéuticos , Derivación y Consulta , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Servicios de Atención de Salud a Domicilio , Hospitalización , Humanos , Enfermedad Iatrogénica/prevención & control , Lactante , Masculino , Persona de Mediana Edad , Pacientes , Servicio de Farmacia en Hospital , Médicos , Estudios Prospectivos , Automedicación , Adulto JovenRESUMEN
Clinical pharmacy has been developed and evaluated in various medical hospital activities. Reviews conducted in this area reported a higher value of this discipline. In surgical services, evenly adverse drug events may occur, so clinical pharmacy activities must also help to optimize the management of drug's patient. The objectives of this literature review is to determine the profile of clinical pharmacy activities developed in surgical services and identify indicators. The research was conducted on Pubmed(®) database with the following keywords (2000-2013), "surgery", "pharmacy", "pharmacist", "pharmaceutical care", "impact" and limited to French or English papers. Studies dealing on simultaneously medical and surgical areas were excluded. Twenty-one papers were selected. The most frequently developed clinical pharmacy activities were history and therapeutic drug monitoring (antibiotics or anticoagulants). Two types of indicators were identified: activity indicators with the number of pharmaceutical interventions, their description and clinical signification, the acceptance rate and workload. Impact indicators were mostly clinical and economic impacts. The development of clinical pharmacy related to surgical patients is documented and appears to have, as for medical patients, a clinical and economical value.
Asunto(s)
Cirugía General/tendencias , Farmacología Clínica/tendencias , Profilaxis Antibiótica , Humanos , Servicios Farmacéuticos , Servicio de Farmacia en Hospital/organización & administración , Servicio de Cirugía en Hospital/organización & administraciónAsunto(s)
Antibacterianos/uso terapéutico , Medicamentos Genéricos/uso terapéutico , Administración Oral , Antibacterianos/administración & dosificación , Antibacterianos/economía , Antibacterianos/normas , Disponibilidad Biológica , Contaminación de Medicamentos , Sustitución de Medicamentos , Medicamentos Genéricos/administración & dosificación , Medicamentos Genéricos/economía , Medicamentos Genéricos/normas , Francia , Humanos , Equivalencia TerapéuticaAsunto(s)
Antibacterianos/efectos adversos , Ciprofloxacina/efectos adversos , Erupciones por Medicamentos/etiología , Metotrexato/efectos adversos , Mucositis/inducido químicamente , Pancitopenia/inducido químicamente , Adulto , Antibacterianos/química , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Antivirales/uso terapéutico , Bicarbonatos/efectos adversos , Bicarbonatos/uso terapéutico , Bleomicina/administración & dosificación , Ciprofloxacina/química , Ciprofloxacina/uso terapéutico , Cristalización , Ciclofosfamida/administración & dosificación , Citarabina/administración & dosificación , Diarrea/inducido químicamente , Doxorrubicina/administración & dosificación , Interacciones Farmacológicas , Etopósido/administración & dosificación , Femenino , Fluidoterapia , Fungemia/complicaciones , Fungemia/tratamiento farmacológico , Humanos , Concentración de Iones de Hidrógeno , Ifosfamida/administración & dosificación , Linfoma de Células B/tratamiento farmacológico , Neoplasias del Mediastino/tratamiento farmacológico , Tasa de Depuración Metabólica/efectos de los fármacos , Metotrexato/administración & dosificación , Metotrexato/sangre , Metotrexato/farmacocinética , Prednisona/administración & dosificación , Solubilidad , Orina/química , Vindesina/administración & dosificaciónAsunto(s)
Acetamidas/uso terapéutico , Antibacterianos/uso terapéutico , Unidades de Cuidados Intensivos/estadística & datos numéricos , Oxazolidinonas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Infección Hospitalaria/tratamiento farmacológico , Utilización de Medicamentos , Femenino , Francia , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Adhesión a Directriz , Hospitales Universitarios/estadística & datos numéricos , Humanos , Linezolid , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Estudios RetrospectivosRESUMEN
AIM: We conducted a retrospective non-interventional cohort study to analyze the impact of proton pump inhibitors co-administration on methotrexate elimination in cancer patients receiving treatment protocol with the antifolate at high dose (>1 g/m(2) intravenously). PATIENTS AND METHODS: Between 2005 and 2008, 79 patients (mean age: 48.8 years; range: 16-76 years) were treated by high dose methotrexate for 197 cycles. RESULTS: Delayed methotrexate elimination (i.e., plasma concentration >15 µmol/l at 24 h, >1.5 µmol/l at 48 h and/or >0.15 µmol/l at 72 h) occurred in 16% (32/197) of the cycles. The co-prescription of a proton pump inhibitor (pantoprazole, lansoprazole, omeprazole, esomeprazole) was found in 53% (17/32) of the courses with delayed elimination and in 15% (24/165) of the cycles without delayed elimination. We identified co-administration of proton pump inhibitors as a major risk factor for delayed elimination (odds ratio 6.66, 95% confidence interval 3.13, 14.17). CONCLUSION: Proton pump inhibitors should not be administered during methotrexate treatment.
Asunto(s)
Antineoplásicos/metabolismo , Metotrexato/metabolismo , Inhibidores de la Bomba de Protones/administración & dosificación , Adolescente , Adulto , Anciano , Antineoplásicos/administración & dosificación , Interacciones Farmacológicas , Humanos , Metotrexato/administración & dosificación , Persona de Mediana Edad , Neoplasias/tratamiento farmacológico , Estudios Retrospectivos , Adulto JovenRESUMEN
Pharmacokinetic drug-drug interactions occur when a drug alters the disposition (absorption, distribution, elimination) of a coadministered agent. Pharmacokinetic interactions may result in the increase or the decrease of plasma drug concentrations. These modifications are variable in intensity but can lead to contraindications of the association. The mechanisms of pharmacokinetic interactions involve drug metabolizing enzymes, drug transporters and orphan nuclear receptors that regulate at the transcriptional level the expression of enzymes and transporters. The increase of drug plasma concentrations is generally related to the inhibition of enzymes and/or drug transport. The decrease of drug concentrations reflects the activation of orphan nuclear receptors by inducers that lead to the increase of the expression of enzymes and drug transporters. Inhibition of drug metabolism or transport is quite immediate (24-48h) while induction is a slower process (7-10 days). Complex situations may be observed with drugs that are both inducers and inhibitors (rifampin, ritonavir). They can cause the decrease and the increase of the exposure of the combined agent depending on the duration of the association.
Asunto(s)
Preparaciones Farmacéuticas/metabolismo , Administración Oral , Antiinfecciosos/uso terapéutico , Antineoplásicos/uso terapéutico , Inhibidores Enzimáticos del Citocromo P-450 , Sistema Enzimático del Citocromo P-450/metabolismo , Interacciones Farmacológicas , Enzimas/genética , Eritromicina/farmacocinética , Eritromicina/uso terapéutico , Humanos , Absorción Intestinal , Cinética , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Receptores Nucleares Huérfanos/metabolismo , Factores de TiempoRESUMEN
OBJECTIVES: Combination of caspofungin and another anti-fungal agent raise expectation of improved efficacy in severe fungal infections including failures to first line therapy. METHODS: We assessed the efficacy and safety of a combination therapy including caspofungin in 17 immunosuppressed or postoperative patients progressive despite standard anti-fungal therapy. RESULTS: The infections included aspergillosis (6), invasive candidiasis (9), mucormycosis (1) and Scedosporium pneumonia (1). Infections had failed one to four prior lines of treatment. The anti-fungal agent combined to caspofungin was either an amphotericin B formulation or an azole. There were 12 favourable responses (71%) and five failures. The survival rate at 3 months was 47%. Eleven patients died within 2-533 days. The causes of death included the initial fungal infection (4), relapse of the infection after switching to oral monotherapy (2), breakthrough aspergillosis (1), and the underlying condition (4). Clinical and renal tolerance were good. Significant hepatic abnormalities were recorded in eight (50%) of the 16 patients evaluable for biological tolerance. CONCLUSION: Caspofungin combined with an azole or with amphotericin B may be of interest in the treatment of serious fungal infections after failure of conventional therapy. Close monitoring of hepatic function is required. These approach should be evaluated in prospective trials.
Asunto(s)
Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Fluconazol/administración & dosificación , Fluconazol/uso terapéutico , Micosis/tratamiento farmacológico , Péptidos Cíclicos/administración & dosificación , Péptidos Cíclicos/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anfotericina B/efectos adversos , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Caspofungina , Preescolar , Quimioterapia Combinada , Equinocandinas , Humanos , Lipopéptidos , Persona de Mediana Edad , Péptidos Cíclicos/efectos adversos , Factores de RiesgoRESUMEN
The Yucatan micropig has been used to develop an experimental model of chronic bacteremia. This animal exhibits clinical and biological characteristics that are close to those in humans, and the pharmacokinetic behaviours of many classes of drugs in this model are similar to those in man. Six adult female were intravenously inoculated with a mean Escherichia coli inoculum of 5.1 x 10(9) bacteria. During five days of spontaneous evolution, the medical follow-up includes biological, clinical and bacteriological parameters. A systemic inflammatory syndrome, a sepsis, an organ insufficiency and positive blood cultures mimic the human disease. In all animals there is an adynamia, a lack of motor coordination, an anorexia, a tachypnea, a fever, a leuconeutropenia followed by an hyperleucocytosis, an anemia, a thrombopenia, an acute tubulonephritis and an elevated sedimentation rate. In some cases, there is an increase of the C reactive protein, in others, an increase of IL-6 and IL-8. At day five, all animals are alive, and five micropigs have positive blood cultures. This chronic, reproducible model is thus suitable for further antibacterial treatments evaluations.
Asunto(s)
Bacteriemia , Modelos Animales , Porcinos Enanos , Lesión Renal Aguda/etiología , Reacción de Fase Aguda , Animales , Anorexia/etiología , Ataxia/etiología , Bacteriemia/sangre , Bacteriemia/complicaciones , Bacteriemia/microbiología , Bacteriemia/patología , Enfermedad Crónica , Progresión de la Enfermedad , Infecciones por Escherichia coli/sangre , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/patología , Fiebre/etiología , Enfermedades Hematológicas/etiología , Interleucina-6/sangre , Interleucina-8/sangre , Insuficiencia Multiorgánica/etiología , Nefritis Intersticial/etiología , Reproducibilidad de los Resultados , Porcinos Enanos/microbiología , Síndrome de Respuesta Inflamatoria Sistémica/etiologíaAsunto(s)
Anciano/psicología , Pacientes Internos/psicología , Relaciones Interpersonales , Violencia/prevención & control , Violencia/psicología , Actitud Frente a la Salud , Enfermería Geriátrica/métodos , Humanos , Institucionalización , Diseño Interior y Mobiliario , Casas de Salud , Calidad de Vida , Factores de RiesgoRESUMEN
Our previous review on the liquid chromatographic (LC) analysis of anti-bacterial agents was published in 1990 in a special issue of the Journal of Chromatography. Eight years later, some new agents have been registered and numerous other are under clinical experiment. In spite of therapeutic problems encountered with certain bacterial pathogens, the development of novel drug candidates has slowed partially due to the need for identification of new bacterial targets and the cost of the research. The present overview updates the LC methods for the quantitations of recent antimicrobial agents (marketed and in clinical development) in human biological fluids. Consideration has been given to procedures permitting the determination of isomers and metabolites as well as methods regarding tissue extracts or liquid sampled from physiological sanctuaries. LC methods are available for the quantitation of almost all registered or investigated recent anti-infective drugs and some are applicable in routine practice. Nevertheless, few techniques have been validated for the determination in tissue extracts limiting the development of penetration studies.
Asunto(s)
Antiinfecciosos/análisis , Antibacterianos/análisis , Antibacterianos/sangre , Antibacterianos/orina , Antiinfecciosos/sangre , Antiinfecciosos/orina , Cromatografía Líquida de Alta Presión , HumanosRESUMEN
Different analytical techniques involving capillary electrophoresis for the determination of drugs and metabolites in biological fluids are described. Pharmacokinetic studies carried out using capillary electrophoresis are presented, as well as the in vitro metabolism investigations. The advantages and the limitations of capillary electrophoresis for pharmacokinetic studies are discussed.
Asunto(s)
Electroforesis Capilar , Preparaciones Farmacéuticas/análisis , Farmacocinética , Animales , Líquidos Corporales/química , Humanos , Preparaciones Farmacéuticas/metabolismoRESUMEN
Since ceftriaxone and itraconazole are highly protein bound, are excreted via a biliary pathway, and are in vitro modulators of the efflux pump P glycoprotein, a pharmacokinetic interaction between these antimicrobial agents can be hypothesized. Therefore, we evaluated the pharmacokinetics of itraconazole and ceftriaxone alone and in combination in a chronic model of catheterized miniature pigs. Itraconazole does not influence ceftriaxone kinetic behavior. The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively. Regarding itraconazole kinetics, ceftriaxone was shown to alter the disposition of the triazole. Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).
Asunto(s)
Antibacterianos/farmacocinética , Antifúngicos/farmacocinética , Ceftriaxona/farmacocinética , Cefalosporinas/farmacocinética , Itraconazol/farmacocinética , Administración Oral , Animales , Antibacterianos/farmacología , Antifúngicos/farmacología , Ceftriaxona/farmacología , Cefalosporinas/farmacología , Interacciones Farmacológicas , Femenino , Inyecciones Intravenosas , Itraconazol/farmacología , Porcinos , Porcinos EnanosRESUMEN
Extended-spectrum beta-lactamases (ESBLs) are found in numerous Enterobacteriaceae, mainly in Klebsiella pneumoniae. We investigated the pharmacodynamics of two new extended-spectrum cephalosporins, cefepime and cefpirome, alone and combined with either amikacin or gentamicin or ciprofloxacin by means of time-kill curves against ESBL-producing, aminoglycoside-resistant K. pneumoniae. When used alone, cefepime (8 and 16 mg/l) resulted in a 2 and 3 log decrease at 6 h, respectively, but at 24 h regrowth occurred. The combination of cefepime (8 mg/l) with amikacin (4 mg/l) resulted in a 4 log decrease at 6 h, but there were no surviving bacteria at 6 h when combined with amikacin (8 mg/l). The combination of cefepime (16 mg/l) with gentamicin (4 mg/l) resulted in a 4 log decrease in 24 h. The antimicrobial combination of cefepime (32 mg/l) with ciprofloxacin (2 mg/l) resulted in a 4 log decrease in 24 h. Cefpirome (8 mg/l) induced a 2 log decrease at 4 h; 32 mg/l cefpirome resulted in a 3 log decrease followed by regrowth at 24 h. The regrowth observed in the late phase with cefpirome alone disappeared when combined with aminoglycoside. When cefpirome (32 mg/l) was used in combination with ciprofloxacin (1 mg/l), it resulted in a 4 log decrease in 24 h.
Asunto(s)
Antibacterianos/farmacología , Cefalosporinas/farmacología , Quimioterapia Combinada/farmacología , Klebsiella pneumoniae/efectos de los fármacos , beta-Lactamasas/biosíntesis , Amicacina/farmacología , Cefepima , Ciprofloxacina/farmacología , Gentamicinas/farmacología , Klebsiella pneumoniae/enzimología , Pruebas de Sensibilidad Microbiana , Factores de Tiempo , CefpiromaRESUMEN
The purpose of our investigation was to evaluate the pharmacokinetic profile of doxorubicin administered by a new schedule. Nine non-pretreated young women with high risk breast cancer (mean age: 38, range: 29-45) entered this trial and received, cyclophosphamide (600 mg/m2) given as a 30-min infusion followed by doxorubicin (120 mg/m2) as a continuous infusion over 6 h. Chemotherapy was combined with hematopoietic factor support (G-CSF or GM-CSF). Blood was sampled over the 0-54 h period and 14 cycles were studied for pharmacokinetics. Doxorubicin as well as its major metabolite doxorubicinol were assayed in plasma specimen by high performance liquid chromatography. Mean doxorubicin plasma concentration peak was 42.6 ng/ml (standard deviation (SD): 13.3). The mean terminal half-lives were 32.6 h (SD: 22.0) and 39.2 h (SD: 21.6) for doxorubicin and doxorubicinol, respectively. Mean areas under the plasma concentration-time curve (AUC) were 413 ng/h-1 ml (SD: 103) and 1,707 ng/h-1 ml (SD: 815) for doxorubicin and doxorubicinol respectively. Consequently, the ratio of the AUC of doxorubicinol to that of doxorubicin was high (mean: 4.1 (SD: 1.6)) contrasting with previous studies reporting ratios less than 1 in patients with normal liver function. The systemic clearance of doxorubicin was 5.23 l/min/m2 (SD: 1.91). The inter- and intra-patient variability for AUC was low for both drugs. Hence the coefficients of variation were 24.6% for doxorubicin, 26.2% for doxorubicinol (inter-individual variation) and less than 10% for both compounds (intra-individual variation). In conclusion, the pharmacokinetic profile of doxorubicin (120 mg/m2) administered as a 6 h-continuous infusion is characterized by a greater exposure to doxorubicinol. This could be explained by a saturation in the biliary excretion process during the period following the end of the infusion.
Asunto(s)
Antibióticos Antineoplásicos/farmacocinética , Neoplasias de la Mama/tratamiento farmacológico , Doxorrubicina/análogos & derivados , Doxorrubicina/farmacocinética , Adulto , Antibióticos Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/sangre , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Esquema de Medicación , Femenino , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Semivida , Humanos , Tasa de Depuración Metabólica , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Three female Yucatan micropigs were included and received a single dose of amikacin (15 mg/kg) by short infusion (30 min) combined either with a single dose of cefepime or cefpirome (30 mg/kg/12 h) or meropenem (7 mg/kg/8 h). The beta-lactams were administered either by intravenous intermittent injection or by continuous infusion. The mean elimination half-life and clearance value of amikacin were 1.88 h and 2.15 ml/min.kg-1 respectively. These pharmacokinetic parameters were similar to those obtained in man (t1/2 = 2,42 h et Cl = 1,61 ml/min kg-1). Furthermore, they were not affected by coadministration of cefepime, cefpirome and to meropenem. While resistant to cefepime, cefpirome and amikacin, Klebsiella pneumoniae producing ESBL was susceptible to combination of these cephalosporins with amikacin in an in vitro/ex vivo micropig model. For the six dosage regimens used in this study, the killing activities were similar and resulted in at least 4 log decrease at 6 h after drug exposure. For antimicrobial combination consisting of bolus dosing of amikacin plus continuous infusion of cefepime or cefpirome, the 12 h serum bactericidal titers (SBTs) were 1:8 for cefepime and 1:2 for cefpirome dosage regimen. When each drug administered intermittently, the 12 h SBTs were 1:4 for cefepime and 1:2 for cefpirome. The 8 h SBTs for dosing schedule containing meropenem combined with amikacin were 1:4 and 1:16 after 30 min short infusion and continuous infusion respectively. In conclusion, our study showed that the micropig model is a reliable model for pharmacokinetic investigation of amikacin. It was concluded that beta-lactam antibiotics tested with amikacin may be coadministered by using the standard recommended dosing regimen of amikacin. Continuous infusion of beta-lactams combined with once dosing of amikacin seems to be as or more effective than intermittent injection of each drug.